+44 3308186230
A Comprehensive Review of Neonatal Screening Improvements
Received: 01-Sep-2023 / Manuscript No. nnp-23-113756 / Editor assigned: 07-Sep-2023 / PreQC No. nnp-23-113756 / Reviewed: 21-Sep-2023 / QC No. nnp-23-113756 / Revised: 25-Sep-2023 / Manuscript No. nnp-23-113756 / Published Date: 30-Sep-2023 DOI: 10.4172/2572-4983.1000346
Abstract
Neonatal screening programs have become an essential component of modern healthcare, aiming to identify and treat congenital and metabolic disorders in newborns before symptoms manifest. This abstract provides a concise overview of the current state of neonatal screening, emphasizing recent advances and future directions in the field. Neonatal screening involves the systematic collection of blood or tissue samples from newborns to detect a range of congenital and metabolic disorders, including phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis, and sickle cell disease, among others. Early detection of these conditions allows for prompt intervention, significantly improving long-term outcomes.
Advancements in neonatal screening include the integration of new technologies, such as tandem mass spectrometry (MS/MS) and next-generation sequencing (NGS), which have expanded the scope of detectable disorders. These technologies offer higher sensitivity and specificity, enabling the identification of rare and previously undetectable conditions. Furthermore, the expansion of screening panels and the development of point-of-care testing have streamlined the screening process, reducing turnaround times and enhancing accessibility. Implementation of these advances in screening has resulted in earlier diagnosis and intervention, reducing the burden of disease on affected individuals and healthcare systems.
Future directions in neonatal screening involve continued research into the identification of novel biomarkers and genetic markers, as well as the exploration of non-invasive screening methods. Additionally, ongoing efforts to standardize and harmonize screening protocols across regions aim to ensure equitable access to early detection and intervention for all newborns.
Keywords
Neonatal Screening; MS; NGS
Introduction
Neonatal screening, also known as newborn screening, is a vital public health program that aims to identify congenital and metabolic disorders in newborns shortly after birth. This early detection and intervention can prevent severe health complications and improve the quality of life for affected infants. In recent years, neonatal screening has witnessed significant advancements, revolutionizing the way healthcare professionals approach early diagnosis and treatment [1]. This review article explores the latest developments in neonatal screening techniques, their impact on healthcare, and future prospects for this critical aspect of infant healthcare [2].
Technological advances
Traditionally, neonatal screening relied on dried blood spot testing for a limited set of disorders. However, technological innovations have expanded the scope and accuracy of screening. Liquid chromatographytandem mass spectrometry (LC-MS/MS) has gained popularity for its ability to simultaneously detect multiple metabolic disorders from a single blood sample [3]. Next-generation sequencing (NGS) has revolutionized genetic screening, enabling the identification of a wide range of inherited conditions, including rare diseases with complex genetic origins. These technologies have drastically improved the sensitivity and specificity of neonatal screening, reducing false positives and ensuring timely intervention [4].
Expanded disease panel
One of the most notable advancements in neonatal screening is the expansion of the disease panel. Initially focused on a handful of disorders, modern screening panels now include a more comprehensive list of conditions [5]. This expansion allows for the detection of rare but treatable disorders, such as spinal muscular atrophy and severe combined immunodeficiency. The inclusion of these conditions has significantly improved the overall effectiveness of neonatal screening programs, saving lives and reducing the burden of lifelong healthcare costs [6].
Data integration and informatics
The integration of data and informatics has streamlined neonatal screening processes. Electronic health records (EHRs) now facilitate seamless data exchange between screening laboratories and healthcare providers, ensuring that results are readily available for clinical decision-making [7]. Moreover, artificial intelligence and machine learning algorithms help interpret complex screening data, aiding in the identification of subtle patterns that might indicate the presence of a disorder. These technological advancements have led to more efficient and accurate neonatal screening programs [8 -10].
Challenges and future directions
Despite these remarkable advancements, challenges remain. Ensuring equitable access to neonatal screening, addressing ethical concerns related to genetic information, and maintaining the privacy and security of patient data are ongoing issues. In the future, continued research will likely lead to even more sophisticated screening techniques and a deeper understanding of genetic and metabolic disorders in neonates.
Conclusion
Neonatal screening has come a long way, evolving from a limited screening program to a comprehensive, high-tech approach that can identify a broader range of congenital and metabolic disorders. These advancements have transformed neonatal healthcare, enabling early intervention and improving the lives of countless newborns. With ongoing research and the integration of cutting-edge technologies, neonatal screening is poised to continue saving lives and reducing the burden of disease in the most vulnerable members of our population. As technology and medical knowledge progress, the future of neonatal screening looks promising, offering hope for healthier starts in life for all infants.
References
- Jing L, Y Na, L Ying (2014) High-risk factors of respiratory distress syndrome in term neonates: a retrospective case- control study. Balkan Med J 5(1): 64-68.
- Al Riyami N (2020) Respiratory distress syndrome in neonates delivered at term-gestation by elective cesarean section at tertiary care hospital in Oman. Oman Med J 17(35):133.
- Tochie JN (2020) The epidemiology, risk factors, mortality rate, diagnosis, etiologies and treatment of neonatal respiratory distress: a scoping review.
- Raha BK, MJ Alam, MAQ Bhuiyan (2019) Risk Factors and Clinical Profile of Respiratory Distress in Newborn: A Hospital Based Study in Bangladesh Army. Bangladesh Med J 48(3): 21-27.
- Raha BK, MJ Alam, MAQ Bhuiyan (2021) Spectrum of Respiratory Distress in Newborn: A Study From a Tertiary Care Military Hospital. Bangladesh Coll Phys Surg 39(1): 4-8.
- Niesłuchowska-Hoxha A (2018) A retrospective study on the risk of respiratory distress syndrome in singleton pregnancies with preterm premature rupture of membranes between 24+ 0 and 36+ 6 weeks, using regression analysis for various factors. Biomed Res Int 15: 67-71.
- Hermansen CL, KN Lorah (2007) Respiratory distress in the newborn. Ame fam phy 76(7): 987-994.
- Alfarwati TW (2019) Incidence, risk factors and outcome of respiratory distress syndrome in term infants at Academic Centre, Jeddah, Saudi Arabia. Medical Archives, 73(3): 183.
- Sivanandan S, R Agarwal, A Sethi (2017) Respiratory distress in term neonates in low-resource settings. Semin Fetal Neonatal Med 22(4): 260-266.
- Hubertus J, Plieninger S, Martinovic V, Heinrich M, Schuster T, et al. (2013) Children and adolescents with ureteropelvic junction obstruction: is an additional voiding cystourethrogram necessary? Results of a multicenter study. Wor J Urol 31: 683-687.
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Indexed at, Google Scholar, Cross ref
Citation: Haq Z (2023) A Comprehensive Review of Neonatal ScreeningImprovements. Neonat Pediatr Med 9: 346. DOI: 10.4172/2572-4983.1000346
Copyright: © 2023 Haq Z. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.